OBJECTIVE: To examine the effects of topically applied recombinant human insulin-like growth factor 1 (IGF1) via gelatin hydrogels on alterations in pure-tone audiometry (PTA) in patients with sudden sensorineural hearing loss (SSHL) refractory to systemic steroids. STUDY DESIGN: Retrospective chart review. SETTING: A single university hospital. PATIENTS: Twenty-five patients with SSHL refractory to systemic steroids who received topical IGF1 treatment. INTERVENTION: Single topical application of IGF1 to the round window niche using gelatin hydrogels. MAIN OUTCOME MEASURES: The primary outcome was alterations in PTA thresholds at frequencies of 0.25, 0.5, 1, 2, and 4 kHz after topical IGF1 application. Secondary outcomes included differences in final improvements in PTA thresholds among frequencies tested and cumulative numbers of patients showing 10- or 20-dB recovery in PTA during the observation period. RESULTS: Topical IGF1 application via gelatin hydrogels significantly altered PTA thresholds at each frequency tested and at the average frequency. The numbers of patients with a 10-dB recovery in PTA increased until 4 weeks after treatment and then stabilized, whereas those patients showing 20-dB recovery gradually increased during the observation period. CONCLUSION: Topical IGF1 application via gelatin hydrogels contributes to the recovery of PTA levels in patients with SSHL refractory to systemic steroids. Major recovery of PTA levels occurs within 4 weeks after treatment.
OBJECTIVE: To examine the effects of topically applied recombinant humaninsulin-like growth factor 1 (IGF1) via gelatin hydrogels on alterations in pure-tone audiometry (PTA) in patients with sudden sensorineural hearing loss (SSHL) refractory to systemic steroids. STUDY DESIGN: Retrospective chart review. SETTING: A single university hospital. PATIENTS: Twenty-five patients with SSHL refractory to systemic steroids who received topical IGF1 treatment. INTERVENTION: Single topical application of IGF1 to the round window niche using gelatin hydrogels. MAIN OUTCOME MEASURES: The primary outcome was alterations in PTA thresholds at frequencies of 0.25, 0.5, 1, 2, and 4 kHz after topical IGF1 application. Secondary outcomes included differences in final improvements in PTA thresholds among frequencies tested and cumulative numbers of patients showing 10- or 20-dB recovery in PTA during the observation period. RESULTS: Topical IGF1 application via gelatin hydrogels significantly altered PTA thresholds at each frequency tested and at the average frequency. The numbers of patients with a 10-dB recovery in PTA increased until 4 weeks after treatment and then stabilized, whereas those patients showing 20-dB recovery gradually increased during the observation period. CONCLUSION: Topical IGF1 application via gelatin hydrogels contributes to the recovery of PTA levels in patients with SSHL refractory to systemic steroids. Major recovery of PTA levels occurs within 4 weeks after treatment.
Authors: Linda Bieniussa; Baran Kahraman; Johannes Skornicka; Annemarie Schulte; Johannes Voelker; Sibylle Jablonka; Rudolf Hagen; Kristen Rak Journal: Front Neurol Date: 2022-06-03 Impact factor: 4.086
Authors: Connie M Sears; Amee D Azad; Linus Amarikwa; Brandon H Pham; Clara J Men; Daniel N Kaplan; Jocelyn Liu; Andrew R Hoffman; Austin Swanson; Jennifer Alyono; Jennifer Y Lee; Chrysoula Dosiou; Andrea L Kossler Journal: Am J Ophthalmol Date: 2022-02-25 Impact factor: 5.488
Authors: Silvia Murillo-Cuesta; Néstor Vallecillo; Rafael Cediel; Adelaida M Celaya; Luis Lassaletta; Isabel Varela-Nieto; Julio Contreras Journal: J Vis Exp Date: 2017-03-08 Impact factor: 1.355